clofazimine has been researched along with meropenem in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Castagnolo, D; Denny, WA; Dos Santos, JL; Fernandes, GFS; Thompson, AM | 1 |
| Chuang, YM; Dutta, NK; Hung, CF; Karakousis, PC; Rubin, H; Wu, TC | 1 |
| Cavanaugh, JS; Cegielski, JP; Dalton, T; Ershova, J; Jou, R; Kurbatova, E; Wu, MH | 1 |
1 review(s) available for clofazimine and meropenem
| Article | Year |
|---|---|
Tuberculosis Drug Discovery: Challenges and New Horizons.
Topics: Antitubercular Agents; COVID-19 Drug Treatment; Drug Discovery; Humans; Mycobacterium tuberculosis; Tuberculosis | 2022 |
5 other study(ies) available for clofazimine and meropenem
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Stringent Response Factors PPX1 and PPK2 Play an Important Role in Mycobacterium tuberculosis Metabolism, Biofilm Formation, and Sensitivity to Isoniazid In Vivo.
Topics: Acid Anhydride Hydrolases; Animals; Antitubercular Agents; Biofilms; Citric Acid Cycle; Clofazimine; Disease Models, Animal; Drug Resistance, Bacterial; Gene Expression; Glycerophosphates; Isoenzymes; Isoniazid; Meropenem; Mice; Mycobacterium tuberculosis; Naphthoquinones; Phosphotransferases (Phosphate Group Acceptor); Polyphosphates; Thienamycins; Tuberculosis Vaccines; Tuberculosis, Multidrug-Resistant; Vaccines, DNA; Xylose | 2016 |
Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
Topics: Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; beta-Lactamase Inhibitors; Clavulanic Acid; Clofazimine; Drug Discovery; Drug Resistance, Multiple, Bacterial; Humans; Leprostatic Agents; Meropenem; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Thienamycins; Tuberculosis, Multidrug-Resistant | 2017 |